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The abnormal accumulation of fluid in two or more fetal space and in some 
cases is associated with placental edema and polyhydramnios. This can be seen in all 
trimesters. It is classified as immune and nonimmune fetal hydrops. Immune hydrops 
fetalis-rhesus alloimmunization and other blood group antibodies cause hemolytic 
disease of the newborn. Nonimmune hydrops fetalis can be largely divided as fetal, 
maternal, placental and idiopathic. Pathophysiology, investigations, treatment and 
counseling are outlined.
Keywords: fetal hydrops, hydrops fetalis, immune hydrops, nonimmune fetal 
hydrops, pathophysiology
1. Introduction
Hydrops fetalis or fetal hydrops is an abnormal fluid collection in two or more 
fetal compartments. This includes skin edema (>5 mm), ascites, pleural, and peri-
cardial effusion. In some, this may be associated with the placental edema (placen-
tal thickness > 4 cm in the second trimester and >6 mm in the third trimester) [1] 
and polyhydramnios [2].
Hydrops fetalis is a serious fetal condition usually identified by ultrasound 
examination. Very rarely, subtle collection of fluid may be missed on ultrasound 
scan. Historically, hydrops fetalis was due to rhesus alloimmunisation, especially 
prior to prophylactic anti-D administration in the developed countries, although 
this may not be the case in many developing countries.
1.1 Terminologies
Hydrops fetalis is the abnormal accumulation of fluid within the fetal skin, 
abdomen, pleural space, and or pericardium [1, 3].
Edema/anasarca is the term for fluid accumulation in the subcutaneous tissues 
of the skin.
Excess fluid accumulation within the peritoneal cavity is frequently referred to 
as ascites.
1.2 Epidemiology
The precise incidence of hydrops fetalis is difficult as some cases spontaneously 
resolve or diagnosis is not seen until fetal demise or miscarriage. The overall inci-




With the advent of anti-D immunoglobulin, the incidence and mortality due to 
immune hydrops fetalis have reduced with an increase in nonimmune fetal hydrops 
in about 90% of cases [5–8].
The diagnosis of hydrops fetalis is usually made antenatally and is a challenging 
condition to counsel and is usually a preterminal manifestation of many different 
pathophysiological conditions.
A recent publication from a single centre in Australia showed that the overall 
survival from diagnosis was 27%. The perinatal mortality risk is high when infants 
are born with hydrops fetalis and is dependent on the underlying diagnosis.
2. Classification
Hydrops fetalis is broadly classified into immune and nonimmune.
2.1 Immune fetal hydrops
Immune hydrops fetalis is due to red cell antibodies. There are many red cell antibod-
ies of which rhesus D, c, and E are the commonest. The incidence of Rh D antibodies is 
reducing secondary due to the widespread use of anti-D at least in the developed coun-
tries. There appears to be an increase in other red cell antibodies that are now commonly 
associated with immune hydrops fetalis that can cause hemolytic disease of the newborn. 
These are kell antibodies, Duffy, and other red cell antibodies. Lewis and p antibod-
ies rarely cause hemolytic disease of the newborn. The mechanism of fetal hydrops is 
secondary to fetal anemia. Fetal anemia is due to direct red cell destruction by the red cell 
antibodies that cross the placenta, especially if the baby has a different blood group and 
type to the mother. Anemia causes high output cardiac failure and fetal hydrops.
In the Caucasian population, about 85% are rhesus (Rh) positive, which leaves 
about 15% Rh negative. When the mother is Rh negative and has never been 
sensitized before (no previous pregnancy, miscarriage, termination of pregnancy, 
or ectopic pregnancy), the sensitization event happens with the first pregnancy 
if the partner is positive. A sensitization event can happen spontaneously during 
pregnancy (feto maternal hemorrhage) and in labour or during an event such as 
maternal trauma, abruption, invasive procedures, antepartum hemorrhage, and 
external cephalic version. During these events, anti-D must be administered in 
Rh-negative women with an Rh positive partner. When possible, partner testing 
for both phenotype and genotype of his blood group must be requested. Currently, 
the widespread use of free fetal DNA in the detection of fetal D gene is helpful in 
identifying the Rh status of the fetus from maternal blood sample performed after 
10 weeks of gestation. Amniocentesis can be performed to assess the fetal Rh D 
status as well; this will again increase the sensitization during pregnancy.
Hydrops fetalis that develop in the absence of red cell hemolysis is termed as 
nonimmune fetal hydrops (NIFH) and was first described by Dr. Potter in 1943. The 
reported incidence of nonimmune fetal hydrops (NIFH) is 1 in 2000–3000 pregnan-
cies [4, 5]. These result in about 3% of perinatal mortality and 50% diagnosed in utero 
will result in fetal demise and 50% of live born will not survive the neonatal period.
2.2 Nonimmune fetal hydrops (NIFH)
There are many causes for nonimmune fetal hydrops. In the past, many were 
thought to be idiopathic. Recent literature review shows that a cause can be identi-
fied prenatally in 65% of cases and up to 85% postnatally [9]. They are broadly 




Hemoglobinopathies (both alpha and beta thalassemia) are caused especially 
when both parents are carriers. Alpha thalassemia can cause severe fetal hydrops 
early in pregnancy, especially Barts [10] hemoglobinopathy (4 gene deletion)—
hemolysis is the cause of fetal hydrops, fetomaternal hemorrhage (abruption), and 
maternal hemolytic anemia.
Infection—some maternal infections can cause fetal infection and affect neural 
development, e.g., cytomegalovirus, toxoplasmosis, parvovirus [11] (erythrogenic), 
syphilis, and Zika virus.
Maternal antibodies—anti-Ro and La antibodies can be positive in mothers 
with autoimmune disorders such as systemic lupus erythematosis, rheumatoid 
arthritis. These mothers are tested for other antibodies including antiphospholipid 
and extractable nuclear antibodies (Ro and La). These antibodies cross the placenta 
and in 6% of cases can cause congenital heart block in the fetus as they affect the 
purkinje fibers of the heart. With a very low heart rate, the fetus is at increased risk 
of developing hydrops [12, 13] (low cardiac output and heart failure).
Neonatal alloimmune thrombocytopenia and idiopathic thrombocytopenia—in 
neonatal alloimmune thrombocytopenia (NAIT), due to incompatible platelet 
antibodies (human platelet antibody A1A and 5A) between maternal and paternal 
platelets, there is production of antibodies against maternal platelets. The risk of 
neonatal thrombocytopenia is very high, 85–100%. These IgG antibodies cross 
the placenta and destroy fetal platelets causing anemia and fetal hydrops. Unlike 
rhesus alloimmunisation where the first pregnancy is less likely to be affected when 
there was no preceding sensitizing event, NAIT affects the first pregnancy (diag-
nosis is made after the affected pregnancy) and increases the risk for subsequent 
pregnancies.
When there is maternal idiopathic thrombocytopenia, the risk of fetal throm-
bocytopenia is low 1–2%, fetal monitoring is recommended both antenatally and 
intrapartum. The risk of fetal thrombocytopenia is high when maternal platelets fall 
below 20 × 106.
2.2.2 Placental
Placental chorioangiomas are tumors of the placenta and is usually a pathologi-
cal diagnosis. When the size of the chorioangiomas is over 5 cms and the cord inser-
tion is close to the chorioangioma, there is an increased vascular turbulence leading 
to microangiopathic anemia leading to fetal hydrops and polyhydramnios.
Monochorionic twin pregnancies—especially in 15% of monochorionic diam-
niotic twin gestations, there is unbalanced vascular communication between the 
twins leading to unbalanced transfusion where one of the twins can be hydropic 
(recipient) or polycythemic, while the other can be anemic. Untreated twin-to-twin 
transfusion [14] leads to fetal hydrops in the recipient and fetal demise in one twin, 
which can in turn result in the death of the other twin as well.
2.2.3 Fetal
There are many fetal conditions that can give rise to fetal hydrops, which can be 
broadly classified as:




• fetal tumors of the face (epignathus) and neck
• cardiac (cardiomyopathies, tumors-rhabdomyomas, myocarditis, and abnor-
mal fetal heart rates such as both fetal tachy and bradyarrhythmias)
• thoracic—pulmonary airway malformations [16] (microcystic or macro-
cystic) especially with mediastinal shift, bronchopulmonary sequestration, 
congenital hyperinflation obstructive airway syndrome, and primary 
lymphatic anomaly
• congenital diaphragmatic hernias—especially with mediastinal shift
• abdomen—tumors or large cysts in fetal abdomen, bowel dilatation, or 
obstruction/volvulus, meconium peritonitis
• sacrococcygeal teratomas—these tumors cause anemia secondary to high-
output cardiac failure
• dental hemangiomas, arteriovenous malformations (AVM’s), absent ductus 
venosus, and umbilical cord varix
• skeletal dysplasias
• cystic hygromas and lymphatic obstruction
3. fetal infections
• toxoplasma, rubella, cytomegalovirus, herpes virus, syphilis, and parvovirus 
are the common fetal infections. Parvovirus is highly erythrogenic, and the 
resulting fetal anemia is due to failed erythropoiesis. There is an estimated 
1–2% risk of seroconversion in pregnancy that increases to 10% during 
epidemics. There is still a fetal loss rate of 3–10% depending on gestational 
age of exposure
4. hematological—secondary to congenital leukemia or red cell eryth-
rogenic abnormalities (Blackfan-Diamond syndrome and congenital 
dyserythropoiesis)
5. fetal metabolic abnormalities, most of them are autosomal recessive—G6PD 
deficiencies
6. fetal genetic or neurologic syndromes
7. miscellaneous—severe fetal growth restriction, fetal akinesia, or hypomobility 
syndromes
8. idiopathic—30–50% of fetal hydrops
Fetal tachyarrhythmia includes supraventricular tachycardia, fetal atrial 
fibrillation, or flutter. In total, 90% of fetal tachyarrhythmia is due to fetal supra-
ventricular tachyarrhythmia. Atrial flutter (FHR > 300 bpm) and fibrillation are 
less common. When fetal heart rates are above 220 bpm, there is reduced diastolic 
filling with reduced ejection fraction and cardiac output. This in turn results in poor 
perfusion, reduced oxygenation, and elevated CVP and hepatic congestion. The risk 
of fetal hydrops is inversely related to gestational age, and this could be related to 
immaturity of fetal myocardium [17].
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Fetal bradyarrhythmias are due to congenital heart block, and fetal hydrops 
is secondary to low cardiac output and inadequate oxygen perfusion and also to 
venous congestion. The risk is higher when FHR is less than 95 bpm and often 
when <65 bpm.
Congenital structural anomalies of the heart may predispose to high output 
failure and may be associated with other chromosomal or structural anomalies [18].
Heritable hemoglobinopathies are usually autosomal recessive, and testing for 
this is done is either done pre or antenatally. Fetal anemia causes high output cardiac 
failure and increased central venous pressure, leading to fetal hydrops. Antiplatelet 
antibodies cross the placenta and destroy fetal platelets similar to rhesus alloim-
munisation, resulting in fetal anemia and hydrops.
Fetal infection that crosses the placenta usually causes myocarditis, suppresses 
erythropoiesis, causes hemolysis, and hepatitis. Examples of fetal infection are 
toxoplasma, cytomegalovirus, rubella, herpes virus, syphilis, parvovirus and others 
include coxsackie virus, Listeria monocytogenes.
Hydrops fetalis is associated with more than 75 inborn errors of metabolism, 
genetic syndromes, and chromosomal abnormalities. The inheritance is usually 
autosomal recessive with some conditions that could be X linked.
Cystic hygromas are usually associated with aberration in lymphatic drainage. 
They are usually seen as cystic spaces in the fetal neck, but can also be seen in fetal 
thorax or abdomen. These findings can be associated with 45XO (Turner’s syndrome) 
[6] and are usually seen in aborted fetuses. There are some cases of spontaneous 
resolution of cystic hygromas, but prognosis is usually poor (90–95% mortality) 
especially when associated with hydrops fetalis even with normal karyotype. The 
differential diagnoses include Noonan syndrome and multiple pterygium syndrome.
Thoracic and abdominal tumors, by way of their size and location, obstruct both 
venous and lymphatic return to the fetal heart, causing fetal hydrops.
In some tumors such as sacrococcygeal teratomas [19] or chorioangiomas, the 
resulting fetal hydrops is not only due to the size of the tumor but also due to the 
increased vascularity in them behaving like an arteriovenous malformation, leading 
to high output cardiac failure, and microangiopathic fetal anemia.
Isolated pleural effusion, unilateral or bilateral, is seen without progression to 
fetal hydrops, especially with abnormal lymphatic development [20].
3. Pathophysiology
There have been many hypotheses for fetal hydrops. Distribution of body water 
is between the intracellular (blood and tissues) and extracellular (plasma, intersti-
tial space, and transcellular) space.
The basic mechanism is an abnormal fluid movement between plasma and tissues 
and the imbalance between the interstitial production and lymphatic return [21].
Four main theories have been postulated:
1. heart failure or obstruction to venous return causes increase in hydrostatic 
capillary pressure,
2. hepatic congestion causing reduced production of albumin causing reduced 
plasma oncotic pressure,
3. lymphatic flow obstruction,
4. damage to peripheral capillary integrity.
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Fluid accumulation may be due to congestive cardiac failure, obstruction to the 
lymphatic flow, or reduced oncotic pressure. The fetus has greater capillary perme-
ability and an interstitial compartment that can accommodate extra fluid.
When there is fetal hypoxia, there is redistribution to the vital organs such as 
brain, heart, and adrenals. There is reduced blood flow to fetal kidneys and gut. The 
reduced renal blood flow activates the renin angiotensin system (RAS) to enhance 
cardiac output. This also increases the venous pressure and thereby increases in 
interstitial fluid accumulation.
Due to reduced hepatic blood flow and increase in extramedullary hematopoiesis, 
there is reduction in albumin production causing hypoalbuminemia, thereby reduc-
ing the oncotic pressure and causing fluid shift. Many animal models have been 
studied in order to understand hydrops. The largest systematic review by Bellini et al. 
[6] also illustrated the possible pathophysiological causes of NIFH (Figure 1).
With fetal hydrops, there is a risk of maternal mirror syndrome (Ballantyne’s syn-
drome) in some patients, where the mother develops edema similar to the hydropic fetus.
Mirror syndrome represents a form of preeclampsia characterized by edema 
(90%), high blood pressure (60%), and proteinuria (40%) of cases [22–25]. The 
incidence is unclear and may not be reported. Review of literature shows a maternal 
mortality of about 20% secondary to pulmonary edema. With treatment for fetal 
hydrops, maternal symptoms have noted to resolve.
The imbalance between the angiogenic and antiangiogenic factors that are 
implicated in severe preeclampsia is also thought to be the underlying pathogenesis 
of this condition. When the underlying NIFH cannot be treated and when there are 
ongoing symptoms of maternal mirror syndrome, delivery is indicated.
4. Investigations
Maternal blood tests—the first line of investigation would be to rule out immune 
hydrops fetalis.
Figure 1. 
Flow chart of possible pathophysiology in NIFH [6].
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Maternal rhesus status, antibodies, full blood count, Kleihauer-Betke test, and 
indirect Coombs test are requested.
The other blood tests are for nonimmune hydrops fetalis.
Hemoglobin electrophoresis is requested to rule out thalassemia, both alpha and 
beta. This screen is especially important in Mediterranean, Indian, and Asian ethnic 
groups.
TORCHS+P serology (toxoplasma, rubella, cytomegalovirus, herpes, syphilis, 
and parvovirus).
If fetal heart rate is lower than 100 bpm, anti-Ro and La antibodies to be 
requested.
Maternal serum electrolytes and liver function tests, including urinary PCR, are 
recommended to rule out maternal mirror syndrome. When fetal hydrops is associated 
with abnormal placenta, triploidy or partial molar pregnancy cannot be ruled out; 
hence, serum beta-HCG and thyroid function tests are performed in this situation.
Figure 2. 
Ultrasound findings fetal hydrops [1]. (A) Pericardial effusions, (B) pleural effusions; note: midline heart 
anterior to small lungs with bilateral effusions, (C) placental thickening, with placenta measuring >4 mm 
in thickness, (D) skin thickening at level of fetal skull, (E) ascites, sagittal, with free-floating loops of bowel 
surrounded by ascites, and (F) ascites in upper abdomen, at level of fetal liver and stomach [1].
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A detailed tertiary ultrasound of the fetus/fetuses is recommended including 
amniotic fluid volume and Doppler studies looking for fetal anemia.
Fetal tertiary ultrasound is the key to diagnose most of the above-men-
tioned fetal structural abnormalities. A thorough assessment including fetal 
weight, morphology, amniotic fluid volume, and placental morphology are 
recommended.
Fetal heart rate documentation is vital to rule out both tachy and brady 
arrhythmias.
Fetal dopplers including umbilical artery, vein, ductus venosus, tricuspid regur-
gitation, and middle cerebral artery peak systolic velocity (MCA PSV) measure-
ments are very helpful in the investigation of hydrops fetalis.
The middle cerebral artery Doppler known as MCA peak systolic velocity is a 
good noninvasive measure of fetal anemia. With fetal anemia and possible hypoxia, 
velocity of blood flow to the fetal brain increases. When the MCA PSV is above 
1.5 multiples of the median (MoM), there is a high risk of fetal anemia. The false-
positive rate of this measurement is around 10% and increases after 35 weeks of 
gestation (Figures 2 and 3).
Invasive testing such as amniocentesis and amniodrainage [26] is discussed and 
performed under ultrasound guidance. Maternal rhesus status is checked so that the 
patient is given anti-D when not sensitized.
The amniotic fluid is sent for chromosome tests—fluorescent in situ hybridiza-
tion (FISH), chromosomal microarray, rasopathy, or hydrops panel including 
Noonan’s syndrome, lysosomal storage disease and in some centres whole exome 
sequencing. Polymerase chain reaction (PCR) from the amniotic fluid is sent for 
fetal infection such as TORCHS+parvovirus’ DNA for specific conditions if known.
When there is evidence of fetal pleural effusion, either a pleural tap or insertion 
of a pleuroamniotic shunt is inserted to drain the pleural effusion/effusions [27]. 
The sample is also sent for lymphocytes apart from infection and karyotype.
The presence of fetal sacrococcygeal teratoma is confirmed, and fetal 
magnetic resonance imaging (MRI) may be required to identify the intrapelvic 
extension.
Figure 3. 
Transverse section of fetal head showing middle cerebral artery—Google images.
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5. Management of NIFH
Transfer to maternal and fetal medicine unit is recommended. The outcome 
for most cases of NIFH is poor unless there is a treatable cause. Women are not 
only extensively counseled [28] regarding outcomes with NIFH, but also for 
risks such as polyhydramnios (29%) and preterm labour (66%). When there is 
an ongoing maternal symptom with severe polyhydramnios, amniodrainage is 
recommended.
The outcome usually falls into
1. Treatable cause of NIFH—fetal tachyarrhythmia’s (antiarrhythmic medications), 
fetal anemia secondary to parvovirus B19 infection (in utero fetal transfusion), 
large macrocystic congenital pulmonary airway malformation (CPAM) (shunt 
or antenatal corticosteroids), twin-twin transfusion syndrome (TTTS) (laser 
photocoagulation), and twin-reversed arterial perfusion (TRAP) (selective 
radiofrequency ablation), fetal sacrococcygeal teratoma’s with an identified fetal 
vessel may benefit from radiofrequency or laser ablation.
2. Lethal prognosis—termination of pregnancy or palliative care should be 
offered.
3. Idiopathic—with uncertain to poor prognosis.
When NIFH is identified before viability with no identifiable cause, pregnancy 
termination should be discussed and offered. Termination of pregnancy should be 
considered when associated with maternal complications such as maternal mir-
ror syndrome. Antepartum surveillance is usually recommended depending on 
gestational age at diagnosis and the underlying cause of NIFH. Once the underlying 
cause of fetal hydrops is treated, ongoing surveillance is important to plan delivery. 
Mode of delivery depends on underlying etiology, gestational age, and maternal 
well-being. Vaginal delivery is considered when there is a lethal condition with no 
fetal monitoring. Cesarean delivery is recommended in all other conditions. When 
there is moderate to severe pleural effusion, drainage prior to delivery may help in 
the neonatal period. Elective preterm delivery is not recommended unless indi-
cated, as this does not improve neonatal outcomes.
In a recent review of a 12-year retrospective cohort from a single centre [9], the 
overall survival from diagnosis was 27% increasing to 55% if born alive.
The long-term prognosis of survivors of NIFH also depends on underlying etiol-
ogy. Following parvovirus B19 infection with fetal anemia and transfusion, there 
appears to be some neurological sequelae in about 30% of babies [29]. This could be 
a direct consequence of parvovirus infection with fetal anemia or transfusion.
Fetuses with supraventricular tachycardia, some babies may develop Wolf 
Parkinson White syndrome later in life [30].
6. Conclusion
Ultrasound is the diagnostic tool for antenatal diagnosis of hydrops fetalis includ-
ing all fetal Doppler studies. A detailed history and examination of the mother is very 
important. Serological testing for perinatal fetal infections and maternal antibodies 
helps in the workup of fetal hydrops. Tertiary referral to a maternal and fetal medi-
cine unit is highly recommended. Outcome for babies with no antenatal diagnosis is 
very guarded to poor with increased neonatal morbidity and mortality.
Complications of Pregnancy
10
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
Author details
Renuka Sekar
Royal Brisbane and Women’s Hospital Brisbane, Queensland, Australia





[1] Norton ME, Chauhan SP, Dashe JS, 
Society for Maternal-Fetal Medicine 
(SMFM). Society for maternal-fetal 
medicine (SMFM) clinical guideline #7: 
Nonimmune hydrops fetalis. American 
Journal of Obstetrics and Gynecology. 
2015;212:127-139
[2] Skoll MA, Sharland GK, Allan LD. Is 
the ultrasound definition of fluid 
collections in non-immune hydrops fetalis 
helpful in defining the underlying cause 
or predicting outcome? Ultrasound in 
Obstetrics & Gynecology. 1991;1:309-312
[3] Désilets V, Audibert F, Society of 
Obstetrician and Gynaecologists of 
Canada. Investigation and management 
of non-immune fetal hydrops. Journal 
of Obstetrics and Gynaecology Canada. 
2013;35:923-936
[4] Hutchison AA, Drew JH, Yu VY, 
et al. Nonimmunologic hydrops fetalis: 
A review of 61 cases. Obstetrics and 
Gynecology. 1982;59:347-352
[5] Graves GR, Baskett TF. Nonimmune 
hydrops fetalis: Antenatal diagnosis 
and management. American Journal 
of Obstetrics and Gynecology. 
1984;148:563-565
[6] Bellini C, Hennekam RC, Fulcheri E, 
et al. Etiology of nonimmune hydrops 
fetalis: A systematic review. American 
Journal of Medical Genetics Part A. 
2009;149A:844-851
[7] Steurer MA, Peyvandi S, Baer RJ, 
et al. Epidemiology of live born infants 
with nonimmune hydrops fetalis-
insights from a population-based 
dataset. The Journal of Pediatrics. 
2017;1(87):182-188
[8] Pasman SA, Oepkes D, et al. 
Hypoalbuminemia: A cause of 
fetal hydrops? American Journal 
of Obstetrics and Gynecology. 
2006;194(4):972-975
[9] Gilby DM et al. Outcomes following 
antenatal identification of hydrops 
fetalis: A single-center experience from 
2001 to 2002. Archives of Disease in 
Childhood-Fetal and Neonatal Edition. 
2018;0:F1-F6
[10] Jomoui W, Sanchaisuriya K, et al. 
Genetic origin of α0-thalassemia 
(SEA deletion) in Southeast Asian 
populations and application to accurate 
prenatal diagnosis of Hb Bart’s hydrops 
fetalis syndrome. Journal of Human 
Genetics. 2017;62(8):747-754
[11] Onroy A et al. Parvovirus B10 
infection during pregnancy and risks 
to the fetus. Birth Defects Research. 
2017;109(5):311-323
[12] Friedman DM et al. Prospective 
evaluation of fetuses with autoimmune 
associated congenital heart block 
followed in the PR interval and 
dexamethasone evaluation study 
(PRIDE) study. The American Journal 
of Cardiology. 2009;103:1102-1106
[13] Ciardulli A et al. Maternal steroid 
therapy for fetuses with immune-
mediated complete atrioventricular 
block: A systematic review and meta-
analysis. The Journal of Maternal-Fetal 
& Neonatal Medicine. 2017:1419182
[14] Van Den Wijingaard JP et al. Twin 
to twin transfusion syndrome modeling. 
Annals of the New York Academy of 
Sciences. 2017;1101:215-234
[15] Alpman A et al. Prenatlly diagnosed 
turner syndrome and cystic hygroma: 
Incidence and reasons for referrals. Fetal 
Diagnosis and Therapy. 2009;25:58-61
[16] Lee FL et al. Treatment of 
congenital pulmonary airway 
malformation induced hydrops fetalis 
via percutaneous scelrotherapy. 




[17] Moodley S et al. Postnatal outcome 
in patients with fetal tachycardia. 
Pediatric Cardiology. 2013;34:81-87
[18] Yuan SM. Cardiac etiologies of hydrops 
fetalis. Zeitschrift für Geburtshilfe und 
Neonatologie. 2017;221(2):67-72
[19] Van Mieghem T. Minimally invasive 
therapy for fetal sacrococcygeal 
teratoma: Case series and systematic 
review of the literature. Ultrasound 
in Obstetrics & Gynecology. 
2014;43(6):611-619
[20] Williams IA et al. Is hydrops fetalis 
a manifestation of pulmonary edema 
caused by impaired lymphatic drainage? 
Ultrasound in Obstetrics & Gynecology. 
2018;31(1):96-99
[21] Bellini C, Hennekam RC. Non-
immune hydrops fetalis: A short review 
of etiology and pathophysiology. 
American Journal of Medical Genetics 
Part A. 2012;158A:597
[22] Braun T et al. Mirror syndrome: A 
systematic review of fetal associated 
conditions, maternal presentation and 
perinatal outcome. Fetal Diagnosis and 
Therapy. 2010;27:191-203
[23] Gedikbasi A et al. Preeclampsia 
due to fetal non-immune hydrops: 
Mirror syndrome and review of 
literature. Hypertension in Pregnancy. 
2011;30:322-330
[24] Goa S et al. Normalization of 
angiognic imbalance after intra-uterine 
transfusion for mirror syndrome caused 
by parvovirus B19. Fetal Diagnosis and 
Therapy. 2013;34:176-179
[25] Llurba E et al. Angiogenic and 
antiangiogenic factors before and 
after resolution of maternal mirror 
syndrome. Ultrasound in Obstetrics & 
Gynecology. 2012;40:367-369
[26] Sandlin AT et al. Clinical relevance 
of sonographically estimated amniotic 
fluid volume: Polyhydramnios. 
Journal of Ultrasound in Medicine. 
2013;32:851-863
[27] Nakayama A et al. The prognostic 
factors of hydrops fetalis with pleural 
effusion. Pediatrics International. 
2017;59(10):1053-1057
[28] Santo S, Thilaganathan B, et al. 
Prenatal diagnosis of non-immune 
hydrops fetalis: What do we tell 
the parents? Prenatal Diagnosis. 
2011;31(2):186-195
[29] Nassr AA et al. Outcome and 
treatment of antenatally diagnosed 
nonimmune hydrops fetalis. 
Fetal Diagnosis and Therapy. 
2018;43(2):123-128
[30] Hahurij ND et al. Perinatal 
management and long-term cardiac 
outcome in fetal arrhythmia. Early 
Human Development. 2011;87:83-87
